Alzheimer’s
disease (AD) is associated with self-assembly
of amyloid β-protein (Aβ) into soluble oligomers. Of the
two predominant Aβ alloforms, Aβ40 and Aβ42, the
latter is particularly strongly linked to AD. Longitudinal studies
revealed a correlation between AD and type 2 diabetes (T2D), characterized
by abnormal insulin levels and insulin resistance. Although administration
of intranasal insulin is explored as a therapy against AD, the extent
to which insulin affects Aβ dynamics and activity is unclear.
We here investigate the effect of insulin on Aβ42 self-assembly
and characterize the capacity of insulin, Aβ42, and Aβ42
co-incubated with insulin to disrupt the integrity of biomimetic lipid
vesicles. We demonstrate that quiescently incubated insulin, which
does not form amyloid fibrils, over time develops membrane-disrupting
capacity, which we propose to originate in misfolded insulin monomers.
These hypothetically toxic misfolded monomers might contribute to
the development of insulin resistance in early stages of T2D that
are associated with abnormally high insulin levels. We show that in
contrast to quiescent incubation, insulin incubated under agitated
conditions readily forms amyloid fibrils, which protect against membrane
permeation. Insulin quiescently incubated with Aβ42 attenuates
both Aβ42 fibril formation and the ability of Aβ42 to
disrupt membranes in a concentration-dependent manner. Our findings
offer insights into interactions between insulin and Aβ42 that
are relevant to understanding the molecular basis of intranasal insulin
as a therapy against Aβ-induced AD pathology, thereby elucidating
a plausible mechanism underlying the observed correlations between
AD and T2D.